Laboratory research advancement in bevacizumab / 中华实验眼科杂志
Chinese Journal of Experimental Ophthalmology
;
(12): 1094-1096, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-636303
ABSTRACT
Vascular endothelial growth factor (VEGF) is a key factor for neovascular diseases of ophthalmology.Bevacizumab is a full-length,humanized monoclonal IgG antibody,which prevents VEGF-A to combine with its receptors on the endothelial surface,and inhibits the endothelial cell proliferation and new blood vessel formation.Nowadays,anti-VEGF drugs are widely used to treat neovascularization diseases in ophthalmology.Bevacizumab has been more extensively applied because of its high security and low cost.The article reviewed the advancement of laboratory researches on the permeability,safety,pharmacokinetics of bevacizumab and research in vitro.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Experimental Ophthalmology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS